Federation des caisses Desjardins du Quebec’s Briacell Therapeutics BCTX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.66K	Sell	455 -750	-62%	-$3.49K	﹤0.01%	2695
2025 Q4	$8.57K	Buy	1,205 +300	+33%	+$3.17K	﹤0.01%	2312
2025 Q3	$9.84K	Buy	905 +555	+159%	+$5.83K	﹤0.01%	2274
2025 Q2	$10.2K	Buy	+350	New	+$12.8K	﹤0.01%	2037

Other funds holding BCTX

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

LCM

LuminArx Capital Management New York $136M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's BCTX Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec reduced its Briacell Therapeutics (BCTX) stake by 62% in Q1 2026, selling an estimated $3.49K and leaving 455 shares worth $1.66K. The position accounts for ﹤0.01% of the portfolio, ranked #2695.

Federation des caisses Desjardins du Quebec first reported a position in BCTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $10.2K in Q2 2025. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

Federation des caisses Desjardins du Quebec held 455 shares of Briacell Therapeutics worth $1.66K as of Q1 2026.
Federation des caisses Desjardins du Quebec sold 750 Briacell Therapeutics shares in Q1 2026, an estimated $3.49K.
Briacell Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #2695 holding.
Federation des caisses Desjardins du Quebec first reported a position in Briacell Therapeutics in Q2 2025 and has held it in 4 quarters since.
Federation des caisses Desjardins du Quebec's Briacell Therapeutics position peaked at $10.2K in Q2 2025.
16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.